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Abstract
Objective: To analyse the feasibility, cost and performance of rapid tuberculosis (TB) molecular and culture systems, in a
high multidrug-resistant TB (MDR TB) middle-income region (Samara, Russia) and provide evidence for WHO policy change.
Methods: Performance and cost evaluation was conducted to compare the BACTECTM MGITTM 960 system for culture and
drug susceptibility testing (DST) and molecular systems for TB diagnosis, resistance to isoniazid and rifampin, and MDR TB
identification compared to conventional Lowenstein-Jensen culture assays.
Findings: 698 consecutive patients (2487 sputum samples) with risk factors for drug-resistant tuberculosis were recruited.
Overall M. tuberculosis complex culture positivity rates were 31.6% (787/2487) in MGIT and 27.1% (675/2487) in LJ (90.5%
and 83.2% for smear-positive specimens). In total, 809 cultures of M. tuberculosis complex were isolated by any method.
Median time to detection was 14 days for MGIT and 36 days for LJ (10 and 33 days for smear positive specimens) and
indirect DST in MGIT took 9 days compared to 21 days on LJ. There was good concordance between DST on LJ and MGIT
(96.8% for rifampin and 95.6% for isoniazid). Both molecular hybridization assay results correlated well with MGIT DST
results, although molecular assays generally yielded higher rates of resistance (by approximately 3% for both isoniazid and
rifampin).
Conclusion: With effective planning and logistics, the MGIT 960 and molecular based methodologies can be successfully
introduced into a reference laboratory setting in a middle incidence country. High rates of MDR TB in the Russian Federation
make the introduction of such assays particularly useful.
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Introduction
Tuberculosis (TB) remains one of the leading causes of
morbidity and mortality globally, focused principally, but not
exclusively, in the non-industrialized world.
Timely diagnosis and prompt treatment of infectious cases are
the key elements of the international effort to combat TB,
providing cure of an individual patient and reducing the spread of
TB by rendering infectious cases non-infectious.
Multidrug-resistant TB (MDR TB), i.e. resistance to at least
isoniazid (Inh) and rifampin (Rif), and extensively drug-resistant
TB (XDR TB), i.e. MDR plus resistance to amikacin, kanamycin
or capreomycin and a fluoroquinolone, are the most problematic
forms of resistance because treatment options are limited and the
second-line drugs used for therapy are more toxic, less effective,
more expensive, and must be administered for a longer period of
time than standard first-line drug therapy [1].
The highest rates of MDR TB in the world (approximately 10%
in new and 25% in re-treatment cases), have been reported from
the Baltic region and countries of the former Soviet Union [2–11].
Conventional culture and DST on solid media is a slow process, and in high
income, low-incidence countries these systems have been supplemented (or
replaced) by automated liquid culture systems such as the Becton Dickinson
BACTECTM MGITTM 960 system. Decreased time to detection, greater
sensitivity than Lowenstein-Jensen (LJ) solid media, comparable sensitivity to
the radiometric Bactec 460 system in detecting Mycobacteria in clinical
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specimens, and good concordance with both LJ and Bactec 460 DST for first-
line drugs (FLD) have been demonstrated in several studies [12–16].
Rapid molecular methods, including commercial or in-house
DNA hybridisation or amplification methods [17] allow detection
of TB and rifampin resistance (and, for some, assays isoniazid
resistance as well) in clinical samples within 1–2 days [18–25].
Despite the demonstrated advantages, the limited data on the
performance, role and value of rapid culture, DST and molecular
detection systems, together with concerns of increased cost and
contamination rates relative to conventional culture on solid
media, have dampened interest and progress in implementing
these systems in low to middle income settings. However, this
situation is changing in response to the growing MDR TB
epidemic and the recent WHO recommendations on the use of
liquid culture and DST and line probe assays (LPAs) [26,27].
This study describes the feasibility of introduction, diagnostic
accuracy and costs of the MGIT rapid culture system for primary
specimens and FLD DST, coupled with rapid molecular systems
for TB culture identification and detection of resistance to
isoniazid and rifampin in Samara, Russia, a middle income region
with a high burden of MDR TB [5,9,28]. The project was
undertaken with the intention (achieved) of producing evidence for
the implementation of global health policy changes relating to TB
diagnosis by the WHO.
Materials and Methods
Ethics statement
The study was approved by the Samara Medical University
Ethics Committee. The study received a waiver of informed
consent because the study used samples that were routinely
collected for use in approved routine tests on LJ media. The tests
on the MGIT 960 system were performed in parallel with the
approved routine tests on LJ media. All aspects related to culture
and phenotypic DST were reviewed and approved by the U.S.
Centers for Disease Control and Prevention as non-human
subjects research which does not require informed consent.
Setting and Design
A programmatic intervention and evaluation was conducted to
compare the feasibility, utility and performance characteristics
(recovery rates, time-to-detection) of the MGIT culture and DST
system (Becton Dickinson, Sparks, MD) and rapid molecular
systems to conventional standard reference LJ-based assays in
patients at high risk of MDR TB in the central TB laboratory of
Samara Region (Category 3 level facility), Russia Federation. The
study was preceded by development of an agreed customer
support plan that included installation and maintenance of the
BACTECTM machine as well as an uninterrupted supply of
reagents needed based on reduced pricing policy offered for
Samara. Principles outlined by the Standards for the Reporting of
Diagnostic accuracy studies (STARD) for diagnostic accuracy
studies were followed.
Prior to implementation into routine practice, MGIT and
molecular methods were quality controlled and validated by the
Health Protection Agency National Mycobacterium Reference
Unit (HPA NMRL) according to the WHO/IUATLD Suprana-
tional Reference Laboratory (SRL) proficiency testing criteria [29]
using a panel of defined M. tuberculosis cultures provided through
the WHO SRL mechanism. Once the laboratory achieved pre-
determined minimum standard efficiency levels based on WHO/
IUATLD Supranational Reference Laboratory proficiency testing
criteria for performance [29] of 80% (E and S), 89% (Inh), and
95% (Rif) in performing MGIT DST, MGIT and LJ culture and
FLD DST were performed in parallel and all results were made
available to clinicians. All staff was formally trained in bacterio-
logical and molecular methods. Staff performing molecular assays
was blinded to culture results and both were blinded to
epidemiological data. This study also evaluated the detailed costs
associated with the introduction of MGIT for TB culture diagnosis
and DST in comparison with conventional methods on solid LJ
media.
Patient Population
Patients were enrolled from 8 TB clinics in Samara Oblast that
are part of a specialised service which provides diagnostics and
treatment for TB patients only. The clinics verify the diagnosis for
patients referred by the general health care sector after initial
screening with a high suspicion for TB. All confirmed or suspected
pulmonary TB patients who were sputum smear-positive and/or
at high risk for MDR TB (individuals with prior TB treatment,
persistent smear-positivity after 3 months treatment and/or poor
clinical improvement, relapse, default, repeated treatment inter-
ruptions, contacts of patients with confirmed MDR TB, homeless
persons and former prisoners) were included.
Patients were excluded if they were currently receiving TB
treatment and smear-converted or remained smear-negative, were
known to be infected with an MDR TB strain, or were suspected
of having extra-pulmonary TB without pulmonary involvement.
Enrolment commenced in April 2006 and continued through
April 2008.
Specimen preparation and primary culture
At least three routine sputum samples were collected from each
patient into 50 ml screw-cap centrifuge tubes (Falcon, Becton
Dickenson, USA) prior to treatment initiation as well as during
treatment as follow-up control samples. Sputum samples were sent
daily from the clinics to the laboratory; specimens were stored at
4uC until processed.
Specimens were processed using the NaOH-NALC method
[30] employing the Becton Dickinson MycoPrepTM kit as
described by the manufacturer. The final concentration of NaOH
(1.0% w/v) was determined during the validation phase to
maintain contamination rates below 8–10%. Concentrated
specimens were stained for the presence of acid-fast bacilli (AFB)
according to the Ziehl-Nielsen method [31].
All processed specimens were immediately inoculated on both
MGIT (0.5 ml inoculum) and LJ media (0.2 ml inoculum).
The MGIT 960 was checked daily for positive and negative
cultures and LJ cultures were checked at least weekly. Although
this standard approach carried an observation bias for time to
detection of positive cultures, it followed the accepted practice of
periodic visual scanning of LJ slopes reported in all previous
published studies of the MGIT and comparable systems and LJ
culture. Tubes flagged as positive by the MGIT 960 instrument
were examined visually for potential mycobacterial growth and
growth was inoculated onto a blood agar plate, subcultured on an
LJ slant and MGIT for DST, and an AFB smear was prepared.
Isolate identification
Cultures were identified as M. tuberculosis complex (MTC)
according to colony morphology, microscopic appearance, and
standard biochemical assays, as specified in the Russian Federal
guidelines [31].
Molecular tests also were used to decrease the time to
identification of MTC. Previous studies suggested that liquid
culture systems would increase the isolation of non-tuberculous
mycobacteria (NTM) as well as M. tuberculosis [32]. Therefore, 327
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consecutive mycobacterial cultures initially isolated on the MGIT
960 system were identified to species level using the GenoTypeH
CM assay (Hain Lifesciences GmbH, Nehren, Germany).
First Line drug susceptibility (DST)
The drug concentrations used in the MGIT system were
(mg/ml): streptomycin (S): 1.0; isoniazid (Inh): 0.1; rifampin (Rif): 1.0;
ethambutol (E): 5.0; pyrazinamide (Z): 100.0 [31,33]. DST on LJ was
performed according to the absolute concentration method, utilizing
the following drug concentrations (mg/ml): S: 10.0; Inh: 1.0; Rif: 40.0;
E: 2.0 [31]. Sensitivity to pyrazinamide is not routinely tested on LJ
media according to Russian Federal guidelines [31].
As the majority of isolates were MTC (see Results), subsequent
cultures were identified using an in-house macroarray, as
described elsewhere [34] and/or a commercial ‘‘line probe’’ assay
system for MTC identification and rifampin and isoniazid
resistance (GenoTypeH MTBDRplus, Hain Lifesciences GmbH,
Germany). Both systems employed the same basic principles i.e.
polymerase chain reaction (PCR) amplification of relevant regions
of genes including the katG and rpoB genes and inhA promoter
region, followed by reverse phase hybridisation to probes
immobilised on a solid phase membrane.
Cost analysis
All laboratory procedures for both LJ andMGIT culture and DST
were broken down into their component parts and a detailed time-
and-motion study was conducted [35–37]. Total salaries, consum-
ables costs, and capital (including equipment) infrastructure costs,
maintenance, administrative and overhead costs of the laboratory, as
well as transport costs were included in the final analysis.
Prices were converted into US dollars (USD) for this analysis.
International pricings for all relevant laboratory resources and
consumables for our study were based on published manufacturer
suggested retail prices (MSRP) in developed countries such as the
US. For local price analysis, procurement pricings specific to
Samara with exceptions to MGIT instrumentation and consum-
ables (for which we used the FIND-Becton Dickinson (BD)
negotiated price available in 2006) were used. The usage of
equipment, reagents, and laboratory space were quantified as
minute used per square meter of space and minutes used.
Overhead costs were calculated and allocated based on time-
observation data particular to building space and staff utilization
for each laboratory procedures included in our cost analysis.
Statistical analysis
All data were obtained from records collected by the clinical
and laboratory staff and entered in a password protected stand-
alone database to maintain confidentiality.
Statistical analysis was performed using the SPSS version 15
package (SPSS, http://www.spss.com). The difference between
rates among different groups was assessed using chi-test (x2).
Results
In total, 698 consecutive patients were recruited into the study
and 2545 sputum samples were subjected to bacteriological
examination on both LJ and MGIT media.
Initially, the MGIT 960 system yielded increased rates of culture
contamination but rates were quickly lowered to 3.4% by meticulous
adherence to the manufacturer’s manual and protocols, and with
rapid transport and/or refrigeration of samples. The samples
collected from patients were immediately refrigerated and stored at
+4 for a maximum time of 48 hours prior to decontamination and
culture. All samples from participating study sites were transported in
cool bags. Sterility checks of water, buffer and NALC solutions and
disposables consumables (such as washes from sputum containers,
cryovials and laboratory tubes used) were regularly run using blood
agar plates. Negative controls of each batch of MGIT tubes and daily
logs of all ready-made solutions were used to monitor any potential
manufacturer’s contamination. In order for any increased culture
speed to be valuable, a rapid molecular identification method was
essential to identify culture growth in 1 day; this also permitted TB
identification in bacterially-contaminated cultures (data not shown).
A proportion of cultures was also spoligotyped to exclude cross-
contamination within the laboratory.
Of the first 327 consecutive patients with positive mycobacterial
isolates, the applied GenoTypeH Mycobacterium CM assay
demonstrated that the vast majority (96.6%) of isolates were M.
Figure 1. Mycobacterial speciation of cultures isolated from sputum specimens.
doi:10.1371/journal.pone.0007129.g001
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tuberculosis complex (Figure 1). Subsequently, molecular methods were
used to test all subsequent isolates simply for the presence or absence
of MTC. Since very few NTMs were isolated, this paper presents
results for MTC only. The overall MTC culture positivity rate for
MGIT and LJ was 31.6% and 27.1% respectively (x2=11.9,
p=0.001); for smear positive specimens it was 90.5% and 83.2%
(x2= 8.6, p=0.003) and for smear negative specimens, 20.4% and
16.4% respectively (x2= 10.7, p=0.001) (Table 1).
The overall proportion of the total MTC isolates (number
confirmed positive cultures by MGIT or LJ/total number positive
cultures by either method) which were positive by MGIT was
97.2% (786/809) compared to 81.1% (656/809) for LJ. Of all
culture positive specimens, 99.2% of smear-positive and 95.5% of
smear-negative specimens were positive by MGIT while LJ
recovery rates were 90.9% for smear-positives and 73.2% for
smear-negative specimens. The concordance of results between
the two systems was high for isolating MTC (92.7%) (Table 2).
Among culture positives, the overall median time to detection of
M. tuberculosis complex was 14 days and 36 days for MGIT and LJ,
respectively. Indirect DST from isolates took an additional 9 days in
MGIT and 21 days on LJ. Therefore, providing a rapid molecular
identification method is available that takes 1–2 days to perform as
in the case of the GenoTypeHMTBDRplusmethod and comparable
methods such as in house in situ hybridisation methods [34,38] the
overall turn-around time can be as short as 25 days for MGIT vs
approximately 60 days for LJ (Figure 2).
Comparative phenotypic DST data for both methods (Table 3)
on all bacteriologically confirmed TB strains demonstrate
approximately 63%, 50%, 27%, 60%, and 10% of the patients
were resistant to isoniazid, rifampin, ethambutol, streptomycin,
and pyrazinamide, respectively. Approximately 50% of cultures
were MDR TB and nearly all rifampin-resistant isolates (98.7%
and 100% detected by LJ and MGIT, respectively) were MDR
TB. There was good concordance between the results obtained by
the LJ and MGIT methods (Table 4) with agreement of 96.8% for
rifampin, 95.6% for isoniazid but only 91.9% for ethambutol and
for 89.5% for streptomycin.
The overall Inh, Rif and MDR resistance rates in the
population as determined by the in-house macroarray (65.7%,
54.6% and 51.0% respectively) and the Hain methods (66.6%,
54.8% and 53.2% respectively) were comparable.
There was good concordance for isoniazid and rifam-
pin resistance between the commercial and in-house low-
density array-based methods (88.5% and 80.7% for
macroarray and 87.3% and 77.9% for Hain; 87.6% and
84.9% for macroarray and 84.4% and 82.2% for Hain
respectively) compared with the MGIT culture or LJ
systems The sensitivity and specificity of both methods
when compared to either culture system were high:
almost 93% and 94% for detection of isoniazid and
approximately 87% and 94% for detection of rifampicin
resistance against the MGIT system; approximately 92%
and 93% for isoniazid and 90% and 93% for rifampicin
against the LJ system respectively (Tables 5–6).
Compared to the LJ method, MGIT culture was consistently
more expensive than LJ regardless of pricing levels but the
difference was small (Table 7). However, the FIND-BD pricing
agreement brings about a 40% reduction in overall costs for
screening one specimen for full first line DST with MGIT at $32
as compared to $56 for full catalogue pricing. LJ methodology
costs ranged from $17 to $20 in Samara and international prices; if
only isoniazid and rifampin resistance was tested the equivalent
costs for Samara and internationally were $13 and $15 for LJ and
$17 and $28 for the MGIT system.
The cost of performing the in-house method (macroarray) in
Samara was calculated based on local wages and overhead costs:
the overall average unit cost of the macroarray test was at about
$15 per specimen. The total chemical and reagent components of
Table 1. MGIT and LJ culture positive sputum specimens by microscopy result (MTC only)*.
Sputum smear status MGIT pos, n, (%) Contaminated,n (%)
Positive and
contaminated, n(%) LJ pos, n (%) Contaminated,n (%)
Positive and
contaminated, n(%)
Smear positive(n-399) 361 (90.5%) 4 (1.0%) 2 (0.5%) 332 (83.2%) 2 (0.5%) 0
Smear negative(n-2088) 426 (20.4%) 81 (3.9%) 11 (0.5%) 343 (16.4%) 8 (0.4%) 1 (0.05%)
Total (n-2487) 787 (31.6%) 85 (3.4%) 13 (0.5%) 675 (27.1%) 10 (0.4%) 1 (0.04%)
*specimens for which both MGIT and LJ results available
doi:10.1371/journal.pone.0007129.t001
Table 2. Recovery rates of each method and concordance compared to all positive cultures (MTC only)*.
Micro-scopy
Recovery rates of each method
compared to all positive cultures
Concordance of MGIT
and LJ culture results
Total N
positive
cultures MGIT+
MGIT
recovery
rate (%) LJ+
LJ
recovery
rate (%) x2, p
MGIT+
and
LJ+
MGIT-
and
LJ-
N
concor-
dant
Concor-
dant
(%)
MGIT+
but LJ-
MGIT-
but LJ+
N discor-
dant
Discor-
dant
(%)
formula a = d+f+g b b/a c c/a d e d+e (d+e)/n f g f+g (f+g)/n
Smear+ (n-393) 362 359 99.2% 329 90.9% 24.6, ,0.001 326 31 357 90.8% 33 3 36 9.2%
Smear- (n-2003) 447 427 95.5% 327 73.2% 83.0, ,0.001 307 1556 1863 93.0% 120 20 140 7.0%
Total(n-2396) 809 786 97.2% 656 81.1% 106.1, ,0.001 633 1587 2220 92.7% 153 23 176 7.3%
*contaminated and indeterminate results excluded, specimens for which both MGIT and LJ results available.
(+) positive test, (2) negative test.
doi:10.1371/journal.pone.0007129.t002
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the test was between $5–6 per specimen (Table 6). The test-strips
used for this method were produced at the HPA MRU, London;
more detailed assessment of the total assay costs when produced in
Russia is needed and is subject of another on-going study.
The costs of the GenoTypeH MTBDRplus assay were not
assessed within this project.
Discussion
This study describes the performance characteristics of rapid
liquid culture (MGIT 960) and molecular assays for the identifica-
tion of MTC, rifampin, isoniazid and MDR TB as well as costs of
the MGIT 960 system when introduced into Samara, a region
within the Russian Federation with high rates of drug resistance and
MDR TB [11].
The MGIT 960 method was quickly taken up by the staff and
successfully introduced into practice in an escalating manner from
primary culture to DST. An initially high contamination rate was
lowered to 3.4% within a month of initiation of the project by
meticulous adherence to manufacturer’s instructions, use of
standard protocols as well as a well-developed system of rapid
sample collection and transport logistics. Coupled with high
recovery rates, it demonstrates that decontamination procedure
was not overly harsh and permitted adequate growth of
mycobacteria while ensuring low contamination rates. A prelim-
inary analysis presented here found that over 96% of positive
cultures were M. tuberculosis complex, suggesting that frequent
NTM isolation (as reported elsewhere [32]) was unlikely to be a
significant problem in this study population. This was probably
due to the high proportion of smear-positivity and drug resistant
TB among enrolled patients, lower HIV-positivity rates compared
to African countries, and dominance of the Beijing family TB
strains in the area. This strain family has been actively transmitted
in the area and has a strong association with drug resistance [5].
Subsequent culture growth was identified using a second
commercial rapid identification system and a non-commercial in
house system for MTC, isoniazid and rifampin resistance which
both employed the same principle of PCR amplification coupled
with a reverse phase hybridisation detection system.
As reported in high-resource, low-TB incidence settings, a
greater proportion of positive cultures from primary specimens
grew in the MGIT system primarily due to increased culture
sensitivity for smear-negative specimens.
The median time for culture isolation was significantly faster for
the MGIT 960 compared to LJ at 14 days versus 36 days for all
specimens in agreement with other international studies mainly
from low incidence [32,39–42].
The proportion of drug resistance was very high in the studied
population – almost half of the isolates were MDR TB. Mono –
resistance to rifampicin was very rarely seen and nearly all
rifampin-resistant isolates were MDR TB suggesting that
rifampin resistance may serve as a reliable surrogate marker for
MDR TB in this population. The median time to obtain DST
results from positive cultures was faster with the MGIT system at
9 versus 21 days for LJ based methods in line with previously
published works mainly from countries with lower levels of drug
resistance [43]. Therefore introduction of the MGIT method can
significantly decrease the overall turn-around time to 25 days
comparable to data reported elsewhere [44]). However, within
Figure 2. Time (days) to culture and DST results for mycobacterial cultures.
doi:10.1371/journal.pone.0007129.g002
Table 3. Phenotypic first-line DST comparing LJ and MGIT
methodology.*
LJ MGIT
N % N %
Total Patients with DST results (Inh+Rif) 319 100.0% 317 100.0%
Any resistance
Any resistance to isoniazid (Inh) 195 61.1% 201 63.4%
Any resistance to rifampin (Rif) 158 49.5% 158 49.8%
Any resistance ethambutol (E) 81 25.4% 84 26.5%
Any resistance to streptomycin (S) 184 57.7% 192 60.6%
Any resistance to pyrazinamide (Z) 33 10.4%
Total Multi-Drug Resistance (MDR) 156 49.8% 158 49.8%
Total poly-resistance other than MDR 36 11.3% 37 11.7%
Total Susceptible 107 33.5% 104 32.6%
*DST was set up one culture per patient; contaminated and undetermined
results excluded
doi:10.1371/journal.pone.0007129.t003
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Table 4. Comparative agreement of LJ and MGIT-based DST methods.
DST
No of concordant
resistant
Total No resistant
any methods % concor-dance
No of concordant
sensitive
Total No sensitive
any methods % concor-dance
Total
agreement
(sensitive and
resistant)%
Inh (n-315) 190 197 96.4% 111 118 94.1% 95.6%
Rif (n-313) 153 158 96.8% 150 155 96.8% 96.8%
E (n-321) 76 89 85.4% 219 232 94.4% 91.9%
S (n-325) 176 193 91.2% 115 132 87.1% 89.5%
* for cultures, on which DST results were available from both methods; 11 MGIT and 9 LJ subcultures were contaminated across all four drugs.
doi:10.1371/journal.pone.0007129.t004
Table 5. Comparison of molecular methods with MGIT culture results for isoniazid and rifampin resistance.
No concordant R1/
Total No R by any
method (%)
No concordant S2/
Total No S by any
method (%)
Total agree-
ment3(S & R) % Sensitivity4, % Specificity5, %
Positive predictive
value6, %
Negative
predictive value7,
%
MA (n-305) Inh 188/207 (90.8%) 97/115 (84.3%) 88.5% 93.5% 93.5% 96.7% 87.8%
Rif 140/177 (79.1%) 124/150 (82.7%) 80.7% 87.8% 94.2% 95.0% 86.2%
Hain (n-311) Inh 193/214 (90.2%) 97/118 (82.2%) 87.3% 93.1% 93.5% 96.6% 87.0%
Rif 148/197 (75.1%) 131/161 (81.4%) 77.9% 86.5% 94.4% 95.1% 84.9%
MA-macroarray method; Hain - GenoTypeH MTBDRplus method (Hain Lifesciences GmbH, Germany).
1: Concordant resistant~
R1R2
R1R2zS1R2zS2R1
4: Sensivity~
R1R2
R1R2zR1S2
2: Concordant sensitive~
S1S2
S1S2zS2R1zS1R2
5: Specificity~
S1S2
S1S2zS1R2
3: Total agreement~
R1R2zS1S2
R1R2zS1S2zS2R1zS1R2
6: Positive predictive value~
R1R2
R1R2zS1R2
7: Negative predictive value~
S1S2
S1S2zS2R1
Where R-resistant and S-sensitive, 1 – by the test method (Hain or Macroarray), 2 – by the reference method (MGIT).
doi:10.1371/journal.pone.0007129.t005
Table 6. Comparison of molecular methods with LJ culture results for isoniazid and rifampin resistance.
No concordant R1/
Total No R by any
method (%)
No concordant S2/
Total No S by any
method (%)
Total agree-
ment3(S & R) % Sensitivity4, % Specificity5, %
Positive predictive
value6, %
Negative
predictive value7,
%
MA (n-305) Inh 195/216 (90.3%) 101/122 (82.8%) 87.6% 92.9% 94.4% 97.0% 87.1%
Rif 152/177 (85.9%) 129/154 (83.8%) 84.9% 90.5% 93.5% 94.4% 89.0%
Hain (n-311) Inh 194/221 (87.8%) 99/126 (78.6%) 84.4% 91.1% 92.5% 96.0% 83.9%
Rif 154/185 (83.2%) 133/164 (81.1%) 82.2% 88.0% 93.0% 93.9% 86.4%
MA-macroarray method; Hain - GenoTypeH MTBDRplus method (Hain Lifesciences GmbH, Germany).
1: Concordant resistant~
R1R2
R1R2zS1R2zS2R1
4: Sensivity~
R1R2
R1R2zR1S2
2: Concordant sensitive~
S1S2
S1S2zS2R1zS1R2
5: Specificity~
S1S2
S1S2zS1R2
3: Total agreement~
R1R2zS1S2
R1R2zS1S2zS2R1zS1R2
6: Positive predictive value~
R1R2
R1R2zS1R2
7: Negative predictive value~
S1S2
S1S2zS2R1
Where R-resistant and S-sensitive, 1 – by the test method (Hain or Macroarray), 2 – by the reference method (LJ).
doi:10.1371/journal.pone.0007129.t006
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the project framework the turn-around-time for positive cultures
and DST ranged from 13 to 87 days with a median of 38 days for
the MGIT. Delays occurred due to logistical problems during the
introduction of the MGIT system into routine use (e.g. reagents
supply), training of additional personnel, contamination and
delays between receiving a culture and subculturing for DST.
One of the advantages of using the MGIT system was an
opportunity to reliably determine sensitivity to pyrazinamide.
This test is not routinely performed on LJ media in Russia due to
the lack of standard protocols and variable standardization
recommended on the national level.Although the MGIT system
generated all FLD DST results more rapidly than the LJ
methodology, the molecular methods provided results for
isoniazid and rifampin resistance within one day. Another study
performed in the same setting of the Samara Regional
Tuberculosis Laboratory presented evidence for efficient use of
molecular assays (GenoTypeH MTBDRplus) directly on smear-
positive sputum samples [45]. The current study demonstrated
that concordance of the commercial and in-house molecular
methods for isoniazid and rifampin resistance was high, with very
close but not complete agreement for isoniazid and rifampin
resistance between the molecular and MGIT defined DST
results. These methods could be implemented as an initial screen
for MDR TB (directly on smear-positive samples or on
mycobacterial cultures isolated from smear-negative samples),
permitting the institution of infection control measures at an
earlier stage, as well as more rapid provision of appropriate
treatment in line with recent WHO recommendations that were
developed with the support of the Samara project data [26]. The
presence of mutations indicating resistance could be used as an
indicator for simultaneously initiating first- and second-line
resistance testing in MGIT, which could significantly reduce the
delay in administering an appropriate drug regimen to an MDR
TB (or XDR TB) case.
The economic analysis demonstrated that although the MGIT
culture system was slightly more expensive than the LJ method
($12 versus $11 respectively), it would permit earlier diagnosis of
TB and prompt treatment initiation (a reduction in median culture
time of 22 days).
Similarly MGIT FLD DST was more expensive than LJ FLD
DST ($56 versus $20 using international prices) but the
difference allowed a significant decrease in diagnostic turn-
around time resulting in earlier identification of drug resistance,
including MDR TB, especially when FLD and SLD DST are set
up simultaneously for isolates which were diagnosed as having
mutations to rifampicin and isoniazid by molecular methods.
Coupled with molecular systems for rapid identification and
drug resistance detection, this would have a significant impact
on a timely administration of an adequate treatment regimen
and potentially improve treatment outcomes. Administration of
timely therapy will render an individual non-infectious and
interrupt transmission; molecular methods and/or MGIT based
DST identify the many patients who have MDR TB (who will
not be rendered non-infectious by standard TB therapy and so
will continue to transmit MDR TB) and culture –based
phenotypic methods are the only way of reliably identifying
the antimicrobials that are able to render MDR TB individuals
non-infectious.
This demonstration project provided much of the evidence
underpinning the diagnostic policy changes relating to bacterio-
logical culture adopted by the WHO in 2007-8. Currently WHO
recommend the routine use of TB liquid culture and DST even in
resource-limited settings to improve diagnosis of TB in general,
MDR TB and smear-negative pulmonary TB including applica-
tion of a rapid method of species identification [27]. The higher
cost of the automated liquid culture media systems is currently
being addressed by the manufacturers by introducing changes into
the pricing policy for the public sector in lower income countries.
This project showed that it is possible to successfully introduce this
technology into resource-constrained settings but that to achieve
satisfactory implementation and performance of the MGIT system
(which is more prone to bacterial contamination due to the greater
sensitivity of liquid media for culture of mycobacteria as well as
other microorganisms compared with solid culture and for DST
which is more complex to perform that using solid culture) key
issues needed to be resolved. These include: (1) availability of
appropriate Category 3 level laboratory infrastructure including
an agreed maintenance plan for the BACTEC system; (2)
repetitive on-site training of laboratory personnel in MGIT
methodology (using detailed SOPs and the system manual) and
molecular methods to create a multi-skilled cadre of staff; (3) initial
expert observation of the performance and implementation of
internal and external quality control of laboratory work; (4)
development of effective logistics for timely collection, storage and
transport of fresh sputum samples to the laboratory as well as the
reporting of results; (5) the creation of algorithms for laboratory
work flow and computerized laboratory record keeping; (6) timely
maintenance of equipment and ensuring a safe continuous supply
of reagents by establishing a commercial contract with a
manufacturer and (7) introduction of a robust stock control system.
For these diagnostic culture systems to have a maximum
therapeutic impact there must be rapid identification of cultures
with the ability to analyse first and second-line DST phenotyp-
ically when molecular tests demonstrate the presence of mutations
encoding rifampin (and possibly isoniazid) resistance in the original
patient specimen or the resulting culture. This will significantly
reduce the time between sputum collection and full susceptibility
testing for MDR TB cases. Addressing timeliness in technological
improvement should go in tandem with minimizing organizational
delay. Clinicians need to make prompt therapeutic changes
following rapid DST analysis.
With effective planning and logistics, an adequate decontamina-
tion protocol and careful training, the MGIT 960 and molecular-
based methodologies can be successfully introduced into a reference
laboratory setting in a middle TB incidence country. The high rates
of MDR TB in the Russian Federation make the introduction of
such assays particularly useful and are likely to translate to other
settings with a high level of drug resistance or where the additional
speed of diagnosis and increased diagnostic sensitivity are of value as
in HIV associated tuberculosis.
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